Esculentoside A inhibits tumor necrosis factor, interleukin-1, and interleukin-6 production induced by lipopolysaccharide in mice

被引:27
作者
Ju, DW
Zheng, QY
Cao, XT
Fang, J
Wang, HB
机构
[1] Second Mil Med Univ, Dept Immunol, Shanghai 200433, Peoples R China
[2] Second Mil Med Univ, Dept Pharmacol, Shanghai 200433, Peoples R China
关键词
esculentoside A; tumor necrosis factor; interleukin-1; interleukin-6; anti-inflammation;
D O I
10.1159/000028197
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Esculentoside A, a kind of saponin isolated from the root of the Chinese herb Phytolaca esculenta, is reported to possess potent anti-inflammatory effects in acute and chronic experimental models. In the present study, we investigated the effects of esculentoside A on the production of tumor necrosis factor (TNF), interleukin-1 (IL-1) and interleukin-6 (IL-6) induced by lipopolysaccharide (LPS) in mice. In vitro experiments demonstrated that esculentoside A (0.1-10 mu mol/l) significantly reduced the release of TNF from the peritoneal macrophages derived from mice pretreated with thioglycolate. IL-1 and IL-6 secretion was also obviously inhibited in a concentration-dependent manner by esculentoside A from 0.01 to 10 mu mol/l. In vivo experiments demonstrated that detectable TNF was observed 0.25 h after injection, was maximal at 0.5 h, and returned to baseline at 4 h. Maximal production of IL-1 and IL-6 were observed to be 1 and 2 h, respectively, after injection of LPS. Pretreatment of mice with 5, 10, or 20 mg/kg esculentoside A once a day for 7 consecutive days dose-dependently decreased the TNF, IL-1 and IL-6 levels in the sera of mice following LPS challenge. TNF, IL-1, and IL-6 are important cytokines involved in the pathogenesis of inflammatory lesions. Inhibition of inflammatory cytokine production may contribute to the anti-inflammatory effects of esculentoside A.
引用
收藏
页码:187 / 195
页数:9
相关论文
共 34 条
[11]   Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-alpha in vitro and in vivo [J].
Fukuzawa, M ;
Satoh, J ;
Sagara, M ;
Muto, G ;
Muto, Y ;
Nishimura, S ;
Miyaguchi, S ;
Qiang, XL ;
Sakata, Y ;
Nakazawa, T ;
Ikehata, F ;
Ohta, S ;
Toyota, T .
IMMUNOPHARMACOLOGY, 1997, 36 (01) :49-55
[12]   INTERLEUKIN-6 IS EXPRESSED IN HIGH-LEVELS IN PSORIATIC SKIN AND STIMULATES PROLIFERATION OF CULTURED HUMAN KERATINOCYTES [J].
GROSSMAN, RM ;
KRUEGER, J ;
YOURISH, D ;
GRANELLIPIPERNO, A ;
MURPHY, DP ;
MAY, LT ;
KUPPER, TS ;
SEHGAL, PB ;
GOTTLIEB, AB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (16) :6367-6371
[13]   INTERLEUKIN-6 AND ITS RELATION TO INFLAMMATION AND DISEASE [J].
HIRANO, T .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1992, 62 (01) :S60-S65
[14]   NITRIC-OXIDE MEDIATES INTERLEUKIN-1 INDUCED-INHIBITION OF GLYCOSAMINOGLYCAN SYNTHESIS IN RAT ARTICULAR-CARTILAGE [J].
JARVINEN, TAH ;
MOILANEN, T ;
JARVINEN, TLN ;
MOILANEN, E .
MEDIATORS OF INFLAMMATION, 1995, 4 (02) :107-111
[15]  
Ju D. W., 1994, Yaoxue Xuebao, V29, P252
[16]  
Ju D. W., 1993, Acta Pharmaceutica Sinica, V28, P721
[17]   EFFECTS OF TRIAZOLODIAZEPINE ON THE PRODUCTION OF INTERLEUKIN-6 FROM MURINE SPLEEN-CELLS AND RABBIT SYNOVIAL-CELLS IN-VITRO [J].
JU, DW ;
ZHENG, QY ;
CAO, XT ;
ZHENG, QH ;
GUAN, XJ ;
WANG, HB .
MEDIATORS OF INFLAMMATION, 1995, 4 (02) :130-132
[18]  
JU DW, 1994, ACTA PHARMACOL SIN, V15, P65
[19]   INTERLEUKIN-1, IMMUNE ACTIVATION PATHWAYS, AND DIFFERENT MECHANISMS IN OSTEOARTHRITIS AND RHEUMATOID-ARTHRITIS [J].
KIRKHAM, B .
ANNALS OF THE RHEUMATIC DISEASES, 1991, 50 (06) :395-400
[20]   THE BIOLOGY OF INTERLEUKIN-6 [J].
KISHIMOTO, T .
BLOOD, 1989, 74 (01) :1-10